Search

Search Constraints

You searched for: Author/Creator Buggisch, Peter

Search Results

1. Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R). (March 2019)

2. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. (25th July 2019)

3. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. (10th August 2018)

4. Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice?. (23rd January 2018)

5. Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection. Issue 9 (September 2015)

6. Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. Issue 1 (December 2017)

7. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Issue 4 (25th February 2017)

8. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry. Issue 9 (5th June 2022)

9. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment. Issue 2 (8th November 2018)

10. Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). Issue 11 (November 2019)